BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors
Condition: Solid Tumors
Sponsor: Boehringer Ingelheim
1403-0001:A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumors
Oral MDM2 inhibitor BI 907828
Cohort 1: Advanced or metastatic MDM2-amplified, TP53 wild type sarcoma with any treatment history
Cohort 2: Advanced or metastatic MDM2-amplified, TP53 wild type non-small cell lung cancer, urothelial carcinoma, biliary tract carcinoma, or pancreatic ductal carcinoma that has been treated with at least 1 line of therapy in the advanced/metastatic setting
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.